Dive into a collection of past posts and rediscover timeless content.
A failed takeover, a Caesars acquisition, and a reverse bid story that flipped the whole narrative overnight create a specific post-chaos entry point for you today.
Most endorsement deals are a cheque and a photo shoot. This one handed the athlete equity, so he now needs the share price to work too.
An $8 billion Amazon deal sent this stock soaring—then the market erased the entire move, setting up a critical test next month.
Three separate board members bought shares within five days of each other. Then an activist investor showed up demanding the CEO be replaced.
A completed biosciences spin-off, and a forward multiple that looks cheap against the peer group make this one of the more interesting setups in healthcare right now.
A cancer trial worked in most patients and fell short in one smaller group. That nuance got flattened into a single ugly day of selling.
Three approved medicines, a near-term Phase 3 readout, and an FDA decision eight days away make this one of the busiest catalyst windows in biotech right now.
This travel software stock grew revenue 38% and cut its loss nearly in half. Now management expects another 30% growth quarter.
Leadership consolidation aimed at driving out costs, plus a consensus pointing to an earnings recovery, make this one worth understanding before the next print.